STOCK TITAN

UNITED THERAPEUTICS (UTHR) CFO sells 10,000 shares after exercising options

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. He exercised 10,000 stock options for Common Stock at an exercise price of $117.76 per share, then sold 10,000 shares of Common Stock in multiple open-market sales on May 26, 2026.

The sales were executed in numerous trades at weighted average prices within ranges from about $558.79 to $578.53 per share and were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, he directly holds 18,876 shares of Common Stock and continues to hold stock options.

Positive

  • None.

Negative

  • None.
Insider EDGEMOND JAMES
Role CFO AND TREASURER
Sold 10,000 shs ($5.73M)
Approx. gross sale proceeds $5.73M
Approx. exercise cost $1.18M
Approx. pre-tax spread $4.55M
Type Security Shares Price Value
Exercise Stock Option 10,000 $0.00 $0.00
Exercise Common Stock 10,000 $117.76 $1.18M
Sale Common Stock 25 $559.5784 $14K
Sale Common Stock 135 $561.2087 $76K
Sale Common Stock 280 $564.0186 $158K
Sale Common Stock 240 $566.3667 $136K
Sale Common Stock 520 $567.3645 $295K
Sale Common Stock 1,040 $568.5377 $591K
Sale Common Stock 760 $569.7903 $433K
Sale Common Stock 700 $570.9212 $400K
Sale Common Stock 860 $571.9323 $492K
Sale Common Stock 440 $572.7024 $252K
Sale Common Stock 281 $574.1309 $161K
Sale Common Stock 809 $575.2417 $465K
Sale Common Stock 1,221 $576.208 $704K
Sale Common Stock 1,929 $577.1302 $1.11M
Sale Common Stock 760 $578.1213 $439K
Holdings After Transaction: Stock Option — 60,000 shares (Direct); Common Stock — 18,876 shares (Direct)
Footnotes (16)
  1. F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
  2. F10. This transaction was executed in multiple trades at prices ranging from $571.45 to $572.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. F11. This transaction was executed in multiple trades at prices ranging from $572.51 to $572.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. F12. This transaction was executed in multiple trades at prices ranging from $573.65 to $574.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. F13. This transaction was executed in multiple trades at prices ranging from $574.71 to $575.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. F14. This transaction was executed in multiple trades at prices ranging from $575.71 to $576.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  7. F15. This transaction was executed in multiple trades at prices ranging from $576.73 to $577.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. F16. This transaction was executed in multiple trades at prices ranging from $577.84 to $578.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  9. F2. This transaction was executed in multiple trades at prices ranging from $558.79 to $559.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  10. F3. This transaction was executed in multiple trades at prices ranging from $560.52 to $561.475. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  11. F4. This transaction was executed in multiple trades at prices ranging from $563.99 to $564.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  12. F5. This transaction was executed in multiple trades at prices ranging from $565.92 to $566.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  13. F6. This transaction was executed in multiple trades at prices ranging from $566.96 to $567.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  14. F7. This transaction was executed in multiple trades at prices ranging from $568.13 to $568.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  15. F8. This transaction was executed in multiple trades at prices ranging from $569.41 to $570.295. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  16. F9. This transaction was executed in multiple trades at prices ranging from $570.45 to $571.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 10,000 shares Common Stock sold in open-market transactions on May 26, 2026
Options exercised 10,000 stock options Exercised into Common Stock at $117.76 per share
Exercise price $117.76 per share Stock option exercise price for 10,000 shares
Sale price range $558.79–$578.53 per share Weighted-average price ranges for multiple sale trades
Post-transaction holdings 18,876 shares Common Stock directly held after the reported transactions
Remaining stock options 60,000 options Stock options outstanding after exercise, expiring March 15, 2027
Rule 10b5-1 plan date October 31, 2025 Date CFO entered into pre-arranged trading plan
Rule 10b5-1 trading plan financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
""security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did UNITED THERAPEUTICS (UTHR) report for CFO James Edgemond?

CFO James Edgemond exercised 10,000 stock options and sold 10,000 shares of UNITED THERAPEUTICS Common Stock in open-market trades on May 26, 2026. These actions were part of a pre-arranged Rule 10b5-1 trading plan disclosed in the filing.

At what prices did UTHR’s CFO sell his UNITED THERAPEUTICS shares?

The reported sales were executed in multiple trades at weighted average prices within ranges from about $558.79 to $578.53 per share. Each transaction range is disclosed, and the filing notes the CFO can provide detailed trade data upon request.

How many UNITED THERAPEUTICS shares does the CFO hold after this Form 4?

Following the reported transactions, CFO James Edgemond directly holds 18,876 shares of UNITED THERAPEUTICS Common Stock. The Form 4 presents this as his direct ownership position after exercising options and selling 10,000 shares in open-market transactions.

What stock options did the UTHR CFO exercise in this Form 4 filing?

He exercised 10,000 stock options for UNITED THERAPEUTICS Common Stock at an exercise price of $117.76 per share. These options relate to a grant with an expiration date of March 15, 2027, as reflected in the derivative transaction details.

Was the UTHR CFO’s share sale under a Rule 10b5-1 trading plan?

Yes, the exercise of stock options and subsequent sale of UNITED THERAPEUTICS shares were executed under a Rule 10b5-1 trading plan. The plan was entered into on October 31, 2025, indicating the transactions were pre-arranged rather than opportunistic.

How many stock options remain after the UTHR CFO’s exercise?

After exercising 10,000 options, the Form 4 shows 60,000 stock options remaining for the CFO in that option award. These options have an exercise price of $117.76 and an expiration date of March 15, 2027, according to the derivative holdings table.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EDGEMOND JAMES

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO AND TREASURER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/26/2026M(1)10,000A$117.7628,876D
Common Stock05/26/2026S(1)25D$559.5784(2)28,851D
Common Stock05/26/2026S(1)135D$561.2087(3)28,716D
Common Stock05/26/2026S(1)280D$564.0186(4)28,436D
Common Stock05/26/2026S(1)240D$566.3667(5)28,196D
Common Stock05/26/2026S(1)520D$567.3645(6)27,676D
Common Stock05/26/2026S(1)1,040D$568.5377(7)26,636D
Common Stock05/26/2026S(1)760D$569.7903(8)25,876D
Common Stock05/26/2026S(1)700D$570.9212(9)25,176D
Common Stock05/26/2026S(1)860D$571.9323(10)24,316D
Common Stock05/26/2026S(1)440D$572.7024(11)23,876D
Common Stock05/26/2026S(1)281D$574.1309(12)23,595D
Common Stock05/26/2026S(1)809D$575.2417(13)22,786D
Common Stock05/26/2026S(1)1,221D$576.208(14)21,565D
Common Stock05/26/2026S(1)1,929D$577.1302(15)19,636D
Common Stock05/26/2026S(1)760D$578.1213(16)18,876D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$117.7605/26/2026M(1)10,00003/15/202303/15/2027Common Stock10,000$0.0060,000D
Explanation of Responses:
1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
2. This transaction was executed in multiple trades at prices ranging from $558.79 to $559.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $560.52 to $561.475. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $563.99 to $564.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $565.92 to $566.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $566.96 to $567.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $568.13 to $568.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $569.41 to $570.295. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $570.45 to $571.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. This transaction was executed in multiple trades at prices ranging from $571.45 to $572.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
11. This transaction was executed in multiple trades at prices ranging from $572.51 to $572.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
12. This transaction was executed in multiple trades at prices ranging from $573.65 to $574.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
13. This transaction was executed in multiple trades at prices ranging from $574.71 to $575.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
14. This transaction was executed in multiple trades at prices ranging from $575.71 to $576.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
15. This transaction was executed in multiple trades at prices ranging from $576.73 to $577.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
16. This transaction was executed in multiple trades at prices ranging from $577.84 to $578.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney05/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)